ENDRA Life Sciences Q1 net loss $2.9M ($0.93/share); cash $2.4M; raised $4.5M in public offering

ENDRA Life Sciences Inc.

Net loss $2.9M ($0.93 per share) in Q1 2023, flat vs $2.9M ($1.33 per share) in Q1 2022.
Operating expenses $2.9M unchanged YoY; cash and equivalents $2.4M at March 31, 2023.
Completed data collection for FDA De Novo submission for TAEUS liver fat device; submission planned mid-2023.
Raised $4.5M net proceeds from public offering subsequent to quarter-end, extending cash runway.
Added 7 patents year-to-date (3 US, 2 Europe, 2 China); IP portfolio now 63 issued patents.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the three months ended March 31, 2023 results: net income $2.9 million, EPS $0.93 per share.

Period: the three months ended March 31, 2023
Net income: $2.9 million
EPS: $0.93 per share
Result: reported results

Exact text from the filing

First Quarter 2023 Financial Results In the first quarter of 2023, our operating expenses were $2.9 million, unchanged from the first quarter in 2022. Increases in research and development and general and administrative expenses were offset by decreases in sales and marketing expenses. Net loss in the first quarter of 2023 was $2.9 million, or $0.93 per share, compared with a net loss of $2.9 million, or $1.33 per share, in the first quarter of 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-006560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.